in image medicine for clinical study illustration
A phase II clinical study of Niclosamide, the anthelmintic medicine for the therapy of covid-19, was begun by the CSIR, Council of Scientific and Industrial Research in conjunction with Laxai Life Sciences Pvt Ltd. The research is an open-label, randomized, multi-center Phase II clinical investigation aimed at assessing the effectiveness, safety, and tolerance of Niclosamide in treating Covid-19 patients hospitalized.
Previously, Niclosamide was widely used in teens and adults for treatments for tapeworm infection. The drug's safety profile was examined over time and was proven to be safe for human consumption at various dose levels, the authorities stated.
"The subject expert committee (SEC) has given its recommendations to conduct this Phase II clinical trial using Niclosamide, which is a generic, affordable drug and easily available in India and therefore can be made available to our population," said Dr. Shekhar C Mande, Director General, CSIR.
Independently, Bengaluru has recently proven that Niclosamide is also a possible SARS-CoV2 inhibitor for entry inhibiting viral invasion via an ionic strength endocytic route, in cooperation with CSIR-IIIM, Jammu, and NCBS. Given the two independent experimental trials, the potential therapeutic candidate in Covid-19 patients currently contains Niclosamide.
"The Active Pharmaceutical Ingredient (API) is being made by Laxai Life Sciences based on improved technology developed at IICT, and the lab is a partner in this important clinical trial, which could provide cost-effective therapeutic options for patients if the trial is successful," Dr. Srivari Chandrashekhar, Director CSIR-II CT Hyderabad said in an official note.
The National Commission for Protection of Child Rights (NCPCR|) has pulled up the Delhi authorities over a promotional video. A criticism on this rega...
The frame of an unidentified guy with one in every of his wrists chopped off turned into discovered close to the farmers’ protest web website on...